GC4419 for Pancreatic Cancer

What is the Purpose of this Study?

We are doing this study to learn if GC4419 can prevent some of the side effects of radiation therapy and allow higher doses of radiation to be used.
What is the Condition Being Studied?
Pancreatic Cancer

Who Can Participate in this Study?

Adults who:

-Have pancreatic cancer that cannot be surgically removed

Age Group
Adults
Participating Institutions

What is Involved?

If you choose to join the study, you will:

-Be randomized (like flipping a coin) into one of two groups:

--Group A will get the study drug (GC4419) and Group B will get a placebo (harmless medicine)

-Have a physical exam

-Have a CT scan

-Complete questionnaires

-Have an endoscopy

-Have a blood draw

Study Details

Full Title
AN ADAPTIVE PHASE I/II DOSE ESCALATION TRIAL OF STEREOTACTIC BODY
RADIATION THERAPY IN COMBINATION WITH RADIOMODULATING AGENT GC4419 IN LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA
Principal Investigator

Contacts
Protocol Number
IRB:
PRO00102370

NCT:
NCT03340974
ClinicalTrials.gov
View on ClinicalTrials.gov